Lange, ChristophDuarte, RaquelFréchet-Jachym, MathildeGuenther, GunarGuglielmetti, LorenzoOlaru, Ioana DOliveira, OlenaRumetshofer, RudolfVeziris, Nicolasvan Leth, FrankEuropean MDR-TB database collaboration2022-02-042022-02-042016-10-15Am J Respir Crit Care Med. 2016 Oct 15;194(8):1029-1031. doi: 10.1164/rccm.201606-1097LE.1073-449Xhttp://hdl.handle.net/10400.18/7935European MDR-TB database collaboration: Sofia Alexandru, Neus Altet, Korkut Avsar, Didi Bang, Raisa Barbuta, Graham Bothamley, Ana Ciobanu, Valeriu Crudu, Manfred Danilovits, Martin Dedicoat, Raquel Duarte, Mathilde Fréchet-Jachym, Gina Gualano, Lorenzo Guglielmetti, Gunar Günther, Jan Heyckendorf, Barbara Kalsdorf, Heinke Kunst, Christoph Lange, Wiel de Lange, Damien Le Dû, Vaira Leimane, Frank van Leth, Rita Macedo, Cecile Magis-Escurra, Anne-Marie McLaughlin, Inge Muylle, Ioana D Olaru, Olena Oliveira, Veronika Polcová, Emanuele Pontali, Cristina Popa, Jérôme Robert, Rudolf Rumetshofer, Alena Skrahina, Varvara Solodovnikova, Victor Spinu, Simon Tiberi, Nicolas Veziris, Piret ViikleppEuropean MDR-TB database collaboration: Rita Macedo, INSA, Portugal[Letters to the Editor]Extract: The emergence of multidrug-resistant tuberculosis (MDR-TB), defined as bacillary resistance to at least rifampicin and isoniazid, threatens global TB control. The number of patients notified with MDR-TB worldwide has increased by 261% from 2009 to 2014, and more than one-third of these patients currently live in the European Region of the World Health Organization (WHO). Management of patients with MDR-TB is challenging owing to the long duration of therapy required to achieve a relapse-free cure, complex drug regimens, frequent drug-related adverse events, high costs, suboptimal adherence, and overall low cure rates. [...]engAntitubercular AgentsClinical ProtocolsDrug Administration ScheduleEligibility DeterminationEuropeHumansTreatment OutcomeTuberculosis, Multidrug-ResistantWorld Health OrganizationPractice Guidelines as TopicInfecções RespiratóriasLimited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe [Letters to the Editor]periodical10.1164/rccm.201606-1097LE